The clinical AI company’s research shows that its new dose verification tool outperformed general-use AI models. It’s Doximity’s latest play to stand out as major AI companies enter healthcare.

As the appetite for clinical AI grows, companies offering specialized medical AI tools are trying to prove that they have accuracy and medical context on their side in a way that general-use AI tools do not.

The research comes at a time when major AI companies like Anthropic and OpenAI are entering the healthcare space, presenting steep competition for industry-specific tools.

Doximity, which claims its clinical AI platform is used by more than 165 health systems, says it tested a handful of large language models released in 2026 by asking them more than 8,500 clinical dosing questions covering more than 2,200 FDA-approved drugs. They checked how often the answers contained errors and how severe those errors were.

Drugs that were freshly approved by the FDA had five times the odds of an error, largely because they are newer to the market and have less real-world safety data compared to established drugs, according to Doximity.

Of the errors detected, 13.2% were minor, 43% were significant and 3.4% were potentially lethal. The most common mistake was failing to adjust doses for age, kidney function or drug interactions, even when that information was given in the question, the report states.

Researchers then tested DoseCheck, Doximity’s new verification tool, and claimed that its dosing findings were correct 99.9% of the time.

The company frames the tool as an additional safety net within Doximity Ask, its AI clinical assistant and medical search engine for clinicians.

Source link